Health brief
AI Diagnostics, Cancer Trials, and War-Induced Outbreaks
Israel's healthcare sector advances with cutting-edge clinical AI and RNA trials while confronting a severe war-related rabies surge.
Health
OpenAI is using Israel's largest hospital to take its clinical tools global — establishing a template for how advanced AI models adapt to local healthcare standards.
BackgroundHospitals are increasingly adopting generative AI to help physicians navigate complex medical literature and patient records. Sheba is Israel's largest medical center and has historically leveraged its ARC innovation wing to pilot advanced healthcare technologies.
- The AI platform will securely synthesize peer-reviewed medical research and clinical guidelines, enabling physicians to diagnose complex or rare cases with greater speed.
- Under the agreement, Sheba will integrate its own localized treatment protocols into OpenAI's models, tailoring recommendations to match Israeli regulatory and clinical standards.
- The partnership secures Sheba's role as a premier testbed for clinical AI, which is expected to attract more international medical technology firms to Israel's digital health ecosystem.
Health
Disrupted border operations have allowed rabies to surge 252% in Israel — turning a manageable veterinary concern into a critical public health threat that strains clinical vaccine supplies.
BackgroundRabies is a fatal viral disease of the central nervous system transmitted through the saliva of infected mammals. Ongoing military conflicts along Israel's northern and southern borders have disrupted routine wildlife vaccination programs, triggering uncontrolled animal migration.
- Domestic dogs now account for the majority of new infections, heavily driven by contact with infected wild jackals and foxes in active combat zones.
- The breakdown of municipal veterinary services and agricultural monitoring near border towns has allowed infected stray animals to migrate unchecked into central Israel.
- Despite the expanding public health threat, the Ministry of Health has yet to fund a dedicated national emergency task force to coordinate local containment efforts.
Health
Silexion is launching its key RNA trial in Tel Aviv first — positioning Israel as a primary clinical testing ground for highly targeted, gene-silencing cancer therapies.
BackgroundPancreatic cancer driven by mutated KRAS genes is notoriously difficult to treat because tumors are often inoperable. Silexion's RNA interference therapy is designed to silence these specific mutated genes, stopping tumor growth when combined with standard chemotherapy.
- The trial will begin with an 18-patient safety phase at Ichilov before expanding to a randomized cohort of roughly 166 patients across global clinical sites.
- Silexion delivers SIL204 via direct injection into the tumor, minimizing the systemic side effects that typically force patients to halt standard chemotherapy.
- The company secured prior regulatory greenlights from both Israel's Ministry of Health and Germany's federal drug agency, clearing a path for rapid European expansion.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.